Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
2,373
Views
0
CrossRef citations to date
0
Altmetric
Immunology
Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective
Erin Johanssona Eli Lilly and Company Ltd, Indianapolis, IN, USACorrespondence[email protected]
View further author information
, View further author information
Massimo Giovannittib Eli Lilly Italy S.p.A, Rome, ItalyView further author information
, Maurizio Mezzettib Eli Lilly Italy S.p.A, Rome, ItalyView further author information
, Na Luc Precision Statistics Consulting, Woodbury, MN, USA
https://orcid.org/0000-0001-5181-7879View further author information
Silvia Sabatinod Eli Lilly Italy S.p.A, Sesto Fiorentino, ItalyView further author information
Pages 1155-1166
|
Received 03 May 2023, Accepted 01 Sep 2023, Published online: 07 Sep 2023
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.